#	Pagina
attuale pagina	/open-h2020/projects/224436/index.html

Opendata, web and dolomites

ABOLED SIGNED

Commercial feasibility of an anti-bacterial treatment

Total Cost €

EC-Contrib. €

Partnership

Views

ABOLED project word cloud

Explore the words cloud of the ABOLED project. It provides you a very rough idea of what is the project "ABOLED" about.

infection multidrug bacteria alternative urgency bacterial public reducing serious economic pass evolution risk commercial care treatments societies infectious burden health prolonged complications ineffective drug remaining illness longer patients pathogenic resistance medicine technologies ing organ compromising amr combat treat modern chemotherapy families transplantation viability infections threat

Project "ABOLED" data sheet

The following table provides information about the project.

Coordinator	THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS Organization address address: NORTH STREET 66 COLLEGE GATE city: ST ANDREWS postcode: KY16 9AJ website: www.st-andrews.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Total cost	0 €
EC max contribution	150˙000 € (0%)
Programme	1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
Code Call	ERC-2019-PoC
Funding Scheme	ERC-POC-LS
Starting year	2019
Duration (year-month-day)	from 2019-08-01 to 2021-01-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS Organization address address: NORTH STREET 66 COLLEGE GATE city: ST ANDREWS postcode: KY16 9AJ website: www.st-andrews.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (ST ANDREWS)	coordinator	150˙000.00

Map

Project objective

Multidrug resistance of pathogenic bacteria has become a serious threat to public health. The need to develop novel technologies to combat the evolution of bacterial drug resistance is clearly a matter of public concern and urgency. The consequences of AMR include (i) reducing our ability to treat common infectious, resulting in prolonged illness and a greater risk of complications; (ii) patients remaining infectious for longer due to ineffective treatments, making them more likely to pass infections on to others; (iii) compromising advances in modern medicine (such as organ transplantation or chemotherapy) due to risk of infection; and (iv) increasing economic burden on health care systems, families, and societies. This project aims to assess the commercial viability of an alternative approach to this problem.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ABOLED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ABOLED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

CountIce (2020)

A portable instrument (PINE) for the autonomous detection of atmospheric ice nucleating particles aimed at the research, global monitoring and cloud seeding markets

PATHOCODE (2020)

Molecular pathology of anti-viral T cell responses in the central nervous system

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks